International Center for Vaccinology

The main tasks of the International Center for Vaccinology are:

• Creation of an international scientific consortium with leading foreign and domestic experts and organizations in order to create, test and put into practice means of specific prevention and therapy of infectious and non-infectious pathologies of animals, birds and humans;
• Conducting research work on promising projects according to the profile of the Center with the involvement of funding;
• Attracting external and strategic investors to projects developed by the Center;
• Providing consulting, consulting, licensing and other services to third-party organizations and individuals on specialized issues of the Center;
• Conducting training courses for specialists and PhD students on specialized issues of the Center.

1. IRN AP08051924 "Development of a new formulation of an allergic vaccine for subcutaneous allergen-specific immunotherapy"

By priority: Life and Health Science.

According to the sub-priority: 5.2. Biotechnologies in medicine; 5.2.5. New biotechnologies for obtaining bio- and medicinal products for preventive medicine.

Funded by: State Institution "Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan".

Years of implementation: 2020-2022.

The total amount of the project is 72,908,000.00 tenge (seventy-two million nine hundred and eight thousand) tenge, including by year:

-for 2020 - in the amount of 24,000,000 tenge (twenty-four million) tenge;

-for 2021-in the amount of 24,400,000 tenge (twenty-four million four hundred thousand) tenge;

-for 2022 -in the amount of 24,508,000 tenge (twenty-four million five hundred and eight thousand) tenge.

The global prevalence of allergic diseases and, at the same time, the disadvantages of commercially available allergen-specific immunotherapy (ASIT) methods makes it necessary to look for new or improved specific treatments of allergies.

Many approaches to improving the ASIT are currently under development, among them the most promising in terms of improving the existing protocols of subcutaneous ASIT is the approach based on the use of adjuvants. With the help of adjuvants, it is possible to significantly reduce the doses of allergens, as well as the number of their injections, which has a positive impact on the safety of this ASIT method. However, the problem is that the most commonly used today (in about 75% of cases) adjuvants of hydroxide or phosphate aluminum have some serious drawbacks, such as the induction of TH2 immune response at the beginning of immunotherapy, neurological pathologies, as well as local undesirable reactions. Therefore, the search for new adjuvants without these drawbacks is an urgent task in the treatment of allergic diseases.

A proposed solution to this problem is the development of a novel allergic vaccine formulation for subcutaneous ASIT based on the innovative AdvaxTM adjuvant or its modification SM55.2™. One of these adjuvants is expected to significantly improve the current protocols for subcutaneous ASIT of allergic rhinitis and bronchial asthma, increasing not only the safety and therapeutic efficacy of the method, but also its convenience for patients.

Technologically, a significant advantage of the proposed novel vaccine formulation is that it is formulated by routinely mixing commercial allergens with AdvaxTM/SM55.2™ adjuvant just before use in the treatment room. Potential

consumers of the project results are public and private medical clinics providing ASIT services, as well as producers of commercial allergens.

The objective of the project is to develop and test a potentially effective, safe and convenient novel allergic vaccine formulation for subcutaneous ASIT of rhinitis and bronchial asthma on a mouse model.

Project tasks:

1) Development of a mouse model of allergic rhinitis and bronchial asthma;

2) Obtaining, testing, and selecting the most effective allergic vaccine formulation for subcutaneous ASIT;

3) Development of the optimal subcutaneous ASIT mode with the selected allergic vaccine formulation on the mouse model;

4) Conducting preclinical studies of the novel allergic vaccine formulation for subcutaneous ASIT.

According to the results of the project research at least 2 (two) articles will be published in peer-reviewed international journals, indexed by Web of Science (from 1-3 quartiles) or having a Cite Score percentile in Scopus database at least 35. In addition, it is planned to obtain one national patent for intellectual property products resulting from the project.

From a scientific perspective, the results of this project are expected to contribute to the development of many other studies aimed at creating new or improving existing ASITs, and thus to influence the allergic field of science. In the long term, the project may contribute to the improvement of the Kazakhstan population's health, the development of allergic services (which are in their infancy) and the reduction of the number of complicated forms of allergic diseases in the future, as well as improving the quality of people life with allergies in general.

This will be addressed through the introduction of a new ASIT method in medical practice, which, due to its advantages, should be in demand in the domestic market of medical services. The project will also train highly qualified specialists in the field of allergology or vaccinology.

Potential consumers of the project results are public and private medical clinics providing ASIT services, as well as producers of commercial allergens.

The results of the project will be disseminated to potential users, scientific communities and the general public through publications in leading peer-reviewed journals, reports at national (including those organized by the authorized body) and 

international conferences, as well as through scientific (Research Gate) and public (facebook) social networks on the Internet. The results of this project will be widely reported in the media, which will lead to the promotion of ASIT as the most appropriate and cost-effective way to treat allergic diseases.

Following the results of the project implementation, the requirement of the contest administrator to submit an application for regional, national and (or) international scientific contests for continuation of research in the chosen scientific direction will also be fulfilled.

2. IRN AP09259609 "A new platform for intranasal SARS-CoV-2 vaccine based on nanoparticles: design development and testing on laboratory animal models"

By priority: The science of life and Health.

According to the sub-priority: SARS CoV-2 (COVID-19) and other potentially pandemic infectious agents.

Funded by: State Institution "Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan".

Years of implementation: 2021-2023.

The total amount of the project is 69,772,258 tenge (sixty-nine million seven hundred seventy-two thousand two hundred fifty-eight ) tenge, including by year:

-for 2021 - in the amount of 19,926,746 tenge (nineteen million nine hundred twenty-six thousand seven hundred forty-six) tenge;

-for 2022 -in the amount of 24,964,647 tenge (twenty-four million nine hundred sixty-four thousand six hundred forty-seven) tenge;

-for 2023-in the amount of 24,880,865 tenge (twenty-four million eight hundred eighty thousand eight hundred sixty-five) tenge.

As a new platform for intranasal SARS-CoV-2 vaccine, the research group of the project proposes to develop and test a design based on chitosan nanoparticles with mannose. The complex of these natural biocompatible polymers, in addition to the ideal transportation of the protein subunits into the mucous membranes, also have a pronounced adjuvant effect. This nanoparticle vaccine formulation was obtained by our panthers at Ohio State University (OSA, USA), and was previously used to develop vaccines against swine flu and poultry salmonellosis. To enhance the T-cell immune response of the nanoparticle vaccine formulation, it is planned to include the adjuvant CpG55.2. (antagonist of the Toll-like receptor 9) developed on the basis of artificial intelligence by our other partner Vaxine Pty Ltd (Adelaide, Australia).

This adjuvant has its unique sequence and is used as an important component of the subunit SARS-CoV-2 vaccine under the trade name COVAX-19 (developer is Vaxine Pty Ltd), which has successfully passed Phase I clinical trial with 40 volunteers in Australia, and is now preparing for Phase II-III clinical trials in 10 countries worldwide. It is important to note that this adjuvant has the potential to reduce the antigenic load of the vaccine by more than 400 times.

The main idea of the proposed project is to combine two advanced technologies for intranasal delivery of antigens based on nanoparticles and adjuvant CpG55.2 (TLR-9 antagonist) to create a new platform for safe, effective and non-injectable SARS-CoV-2 vaccine. Achieving the latter makes it possible to eliminate a number of issues (pain, cross-contamination, needle damage, insufficient or over-dosing, increased costs, as well as fear of injections) associated with vaccination.

The aim of the project is to develop a novel safe, immunogenic and effective platform for SARS-CoV-2 nanoparticle vaccine with intranasal administration.

In order to achieve the objective, the following tasks are set:

1) Construction and generation of recombinant S1/RBD proteins of SARS-CoV-2 virus;

2) Development of a laboratory animal model to evaluate the vaccine effectiveness;

3) Obtaining safe and effective SARS-CoV-2 nanoparticle vaccine formulations for intranasal application;

4) SARS-CoV-2 nanoparticle vaccine stability assessment in storage and transport conditions;

5) Study of immunobiological properties of SARS-CoV-2 vaccine on laboratory animal model.

A novel safe, immunogenic and effective SARS-CoV-2 nanoparticle vaccine platform with intranasal application will be developed. This platform will include two advanced technologies from our international partners - intranasal delivery of antigens based on nanoparticles and adjuvant CpG55.2 (TLR-9 antagonist).

New scientific data on safety, immunogenicity and efficacy of the novel vaccine platform in different laboratory animal models will be obtained. A minimum of 1 (one) original or review paper will be published in a peer-reviewed journal included in 1 (first) quartile (Q1) in the Web of Science and/or having a CiteScore percentile in the Scopus database of at least 80 (presumably in Vaccine [percentile 98; https://www.journals.elsevier.com/vaccine] or npj Vaccines [percentile 87; https://www.nature.com/npjvaccines/] or other), and one application for an invention will be submitted to the National Patent Office. In case of success, the created platform may serve first as a subject for investment and then licensing by local and possibly global pharmaceutical companies (foreign partners of the project will support this). It may also serve as a basis for developing vaccines against other respiratory viral infections, including those with pandemic potential.

It is expected that the updated SARS-CoV-2 virus recombinant S1/RBD proteins will be purchased by the Kazakhstan diagnostic company OMICRON 3D LLP, which plans to use them to increase the sensitivity and specificity of its COVID-19 ELISA kits. Due to its interest, this company is acting as a private partner of the proposed project and has signed a corresponding co-financing agreement.

The project aims to counteract the current COVID-19 and future pandemics with the use of advanced technologies, and therefore is in line with the global scientific practices world science trend. Therefore, its implementation will allow increasing the level and potential of research works, as well as the competitiveness of KZ Kazakhstani scientific organizations and their teams.

1. Research on the Development of COVID-19 Vaccines for Public Health:

The Center has made significant progress in developing COVID-19 vaccines. They have successfully developed two new vaccines against COVID-19, namely NARUVAX-C19 (a subunit vaccine for intramuscular administration) and NARUVAX-C19/Nano (a nanovaccine for nasal spraying). Preclinical studies of these vaccines have been conducted at the National Center of Drug and Medical Devices Expertise of the Committee for Medical and Pharmaceutical Control, Ministry of Health of Kazakhstan (NCEMS).

Both NARUVAX-C19 and NARUVAX-C19/Nano vaccines have undergone comprehensive testing and have demonstrated positive results. They have been deemed safe and recommended for further clinical trials, as indicated in the NCEDC Reports #DI2021-29 dated March 31, 2022, and Report #DI2021-28 dated March 31, 2022. Furthermore, the NARUVAX-C19 vaccine has also undergone preclinical testing on non-human primates (rhesus macaques) at the Research Institute of Medical Primatology in Sochi, Russia.

These vaccines have been included in the World Health Organization's registry as promising vaccine candidates against COVID-19. They are considered effective platforms for managing and controlling future pandemics in Kazakhstan.

2. Research on the Development of a Veterinary Vaccine Against SARS-CoV-2 Virus Infection.

The Center has also conducted research on the development of a veterinary vaccine targeting the SARS-CoV-2 virus. A new subunit vaccine called NARUVAX-C19 (pets) has been developed specifically for carnivores and other animals that are susceptible to COVID-19 infection.

The NARUVAX-C19 (pets) vaccine has shown to be safe and highly effective in cats. It holds potential for use in other susceptible wild carnivores such as minks, tigers, lions, leopards, snow leopards, and more, which can also be affected by the SARS-CoV-2 virus.

This development marks a significant advancement in safeguarding the health of animals and mitigating the spread of the virus among different species.

3. Research on the Creation of an Allergy Vaccine for Public Health.

The Center has undertaken research focused on developing an allergy vaccine to address public health concerns. Specifically, a new vaccine named PollenVax has been developed for the immunotherapy of allergic rhinitis and bronchial asthma caused by wormwood pollen, which is considered one of the top ten global aeroallergens.

PollenVax has reached NASA Technology Readiness Level 5 (TRL-5) according to the BIRAC biotechnology (vaccine) scale, indicating significant progress in its development and readiness for further testing and implementation.

To ensure its safety, a preclinical study of the PollenVax vaccine was conducted at the GLP testing laboratory of the NCELS. The study demonstrated that the PollenVax vaccine has no toxic effects on the body, exhibits good tolerability, and does not induce allergic responses in laboratory animals, including pregnant animals, as stated in the NCEDLVax report №DI2022-07 dated October 28, 2022.

Based on these findings, the NCED has recommended the PollenVax vaccine for further clinical trials, reflecting the promising potential of this vaccine for addressing allergic rhinitis and bronchial asthma caused by wormwood pollen.

4. Patent Work.

The Center has made significant progress in patenting their inventions. They have successfully obtained five national patents for different strains of the SARS-CoV-2 virus, COVID-19 vaccines, and allergy vaccines. Additionally, an application for a Eurasian patent for an allergy vaccine has been submitted.

Furthermore, the Center has filed an international patent application numbered "NANOTECHNOLOGY BASED INTRANASAL COVID-19 VACCINE COMPRISING CHITOSAN" with the patent number №63/417,817 on October 20, 2022. This international patent application highlights their innovative approach to developing an intranasal COVID-19 vaccine using chitosan-based nanotechnology.

The Center's dedication to patenting their inventions showcases their commitment to protecting their intellectual property and advancing their research in the field of vaccines and treatments for various diseases.

5. Publication Activity.

During the period of 2020-2022, the Center has actively published research articles in international peer-reviewed journals. They have published a total of 16 articles, with 14 (87.5%) of them appearing in Q1 journals and 2 (12.5%) in Q3 journals, as per the categorization by WoS (Web of Science).

The research articles published by the Center have garnered significant attention and impact within the academic community. In the years 2021-2022, these articles generated citations that accounted for approximately 21.8% to 28% of the total citations attributed to Kazakh National Agrarian Research University (KazNARU).

This publication activity highlights the Center's commitment to contributing valuable research findings to the scientific community and establishing their presence as a reputable institution in the field of vaccine development and related research.

6. Educational Activities.

In addition to its research endeavors, the Center also actively engages in educational activities by providing training opportunities for students pursuing advanced degrees. Currently, the Center is involved in training three PhD doctoral students and one master's student from Kazakh National Agrarian Research University (KazNARU), Kazakh National Medical University named after S.D. Asfendiyarov (KazNMU), and Karaganda Medical University.

By mentoring and supporting these students, the Center contributes to the development of future professionals in the field of medical and veterinary research. This educational engagement further strengthens the Center's commitment to knowledge dissemination and nurturing young talent in the realm of vaccine development and related disciplines.

Publications of the center's employee

1.Tabynov K, Turebekov N, Babayeva M, Fomin G, Yerubayev T, Yespolov T, Li L, Renukaradhya GJ, Petrovsky N, Tabynov K. An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission. NPJ Vaccines. 2022 Feb 23;7(1):24. https://doi.org/10.1038/s41541-022-00450-8

2.Tabynov K, Orynbassar M, Yelchibayeva L, Turebekov N, Yerubayev T, Matikhan N, Yespolov T, Petrovsky N, Tabynov K. A Spike Protein-Based Subunit SARS-CoV-2 Vaccine for Pets: Safety, Immunogenicity, and Protective Efficacy in Juvenile Cats. Front Vet Sci. 2022 Mar 14;9:815978. https://doi.org/10.3389/fvets.2022.815978

3.Tabynov K, Babayeva M, Nurpeisov T, Fomin G, Nurpeisov T, Saltabayeva U, Renu S, Renukaradhya GJ, Petrovsky N, Tabynov K. Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model. Front Immunol. 2022 Mar 15;13:828690. https://doi.org/10.3389/fimmu.2022.828690

4.Babayeva M, Tabynov K, Nurpeisov T, Fomin G, Renukaradhya GJ, Petrovsky N, Tabynov K. A recombinant Artemisia vulgaris pollen adjuvanted Art v 1 protein-based vaccine treats allergic rhinitis and bronchial asthma using pre- and co-seasonal ultrashort immunotherapy regimens in sensitized mice. Front Immunol. 2022 Nov 9;13:983621. https://doi.org/10.3389/fimmu.2022.983621

5.Parekh FK, Hay J, Tabynov K, Hewson R, Fair JM, Essbauer S, Yeh KB. Cooperative Research and Infectious Disease Surveillance: A 2021 Epilogue. Front Public Health. 2022 Jan 24;9:817431. https://doi.org/10.3389/fpubh.2021.817431

6.Renu S, Wilson HL, Tabynov K, Hiremath J. Editorial: Engineered Adjuvants and Carriers for an Animal Infectious Disease Vaccine. Front Bioeng Biotechnol. 2021 May 21;9:692634. https://doi.org/10.3389/fbioe.2021.692634

7.Yeh KB, Tabynov K, Parekh FK, Maltseva E, Skiba Y, Shapiyeva Z, Sansyzbai A, Frey S, Essbauer S, Hewson R, Richards AL, Hay J. Building Scientific Capability and Reducing Biological Threats: The Effect of Three Cooperative Bio-Research Programs in Kazakhstan. Front Public Health. 2021 Oct 12;9:683192. https://doi.org/10.3389/fpubh.2021.683192

8.Zhugunissov K, Kilibayev S, Mambetaliyev M, Zakarya K, Kassenov M, Abduraimov Y, Bulatov Y, Azanbekova M, Absatova Z, Abeuov K, Nurgaziev R, Renukaradhya GJ, Tabynov K. Development and Evaluation of a Live Attenuated Egg-Based Camelpox Vaccine. Front Vet Sci. 2021 Aug 16;8:721023. https://doi.org/10.3389/fvets.2021.721023

9.Yeh KB, Parekh FK, Tabynov K, Tabynov K, Hewson R, Fair JM, Essbauer S, Hay J. Operationalizing Cooperative Research for Infectious Disease Surveillance: Lessons Learned and Ways Forward. Front Public Health. 2021 Sep 10;9:659695. https://doi.org/10.3389/fpubh.2021.659695

10.Yeh KB, Tabynov K, Parekh FK, Mombo I, Parker K, Tabynov K, Bradrick SS, Tseng AS, Yang JR, Gardiner L, Olinger G, Setser B. Significance of High-Containment Biological Laboratories Performing Work During the COVID-19 Pandemic: Biosafety Level-3 and -4 Labs. Front Bioeng Biotechnol. 2021 Aug 13;9:720315. https://doi.org/10.3389/fbioe.2021.720315

11.Ryskeldinova S, Zinina N, Kydyrbayev Z, Yespembetov B, Kozhamkulov Y, Inkarbekov D, Assanzhanova N, Mailybayeva A, Bugybayeva D, Sarmykova M, Khairullin B, Tabynov K, Bulashev A, Aitzhanov B, Abeuov K, Sansyzbay A, Yespolov T, Renukaradhya GJ, Olsen S, Oñate A, Tabynov K. Registered Influenza Viral Vector Based Brucella abortus Vaccine for Cattle in Kazakhstan: Age-Wise Safety and Efficacy Studies. Front Cell Infect Microbiol. 2021 Jul 1;11:669196. https://doi.org/10.3389/fcimb.2021.669196

12.Bugybayeva D, Kydyrbayev Z, Zinina N, Assanzhanova N, Yespembetov B, Kozhamkulov Y, Zakarya K, Ryskeldinova S, Tabynov K. A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model. Infect Dis Poverty. 2021 Feb 16;10(1):13. https://doi.org/10.1186/s40249-021-00801-y

13.Zhang L, Wang L, Cao S, Lv H, Huang J, Zhang G, Tabynov K, Zhao Q, Zhou EM. Nanobody Nb6 fused with porcine IgG Fc as the delivering tag to inhibit porcine reproductive and respiratory syndrome virus replication in porcine alveolar macrophages. Vet Res. 2021 Feb 17;52(1):25. https://doi.org/10.1186/s13567-020-00868-9

14.Hiremath J, Renu S, Tabynov K, Renukaradhya GJ. Pulmonary inflammatory response to influenza virus infection in pigs is regulated by DAP12 and macrophage M1 and M2 phenotypes. Cell Immunol. 2020 Jun;352:104078. https://doi.org/10.1016/j.cellimm.2020.104078

15.Mailybayeva A, Ryskeldinova S, Zinina N, Zhou EM, Renukaradhya GJ, Tabynov K. Evaluation of Duration of Immunogenicity and Protective Efficacy of Improved Influenza Viral Vector-Based Brucella abortus Vaccine Against Brucella melitensis Infection in Sheep and Goats. Front Vet Sci. 2020 Feb 27;7:58. https://doi.org/10.3389/fvets.2020.00058

16.Bugybayeva D, Ryskeldinova S, Zinina N, Sarmykova M, Assanzhanova N, Kydyrbayev Z, Tabynov K. Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing Brucella Immunodominant Proteins in Mice and Guinea Pigs. Biomed Res Int. 2020 Nov 19;2020:1438928. https://doi.org/10.1155/2020/1438928

17.Yeh KB, Parekh FK, Musralina L, Sansyzbai A, Tabynov K, Shapieva Z, Richards AL, Hay J. A Case History in Cooperative Biological Research: Compendium of Studies and Program Analyses in Kazakhstan. Trop Med Infect Dis. 2019 Nov 9;4(4):136. https://doi.org/10.3390/tropicalmed4040136

18.Nurpeisova A, Kassenov M, Rametov N, Tabynov K, Renukaradhya GJ, Volgin Y, Sagymbay A, Makbuz A, Sansyzbay A, Khairullin B. Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine. Arch Virol. 2019 Apr;164(4):1027-1036. https://doi.org/10.1007/s00705-019-04147-7

19.Mambetaliyev M, Yesimbekova NB, Strochkov VM, Tabynov KK, Sultankulova KT, Abduraimov YO. The evidence of occurrence of porcine circovirus 2 isolation and characterization in Kazakhstan. Virusdisease. 2018 Mar;29(1):118-122. https://doi.org/10.1007/s13337-018-0436-6

20.Orynbayev MB, Fereidouni S, Sansyzbai AR, Seidakhmetova BA, Strochkov VM, Nametov AM, Sadikaliyeva SO, Nurgazieva A, Tabynov KK, Rametov NM, Sultankulova KT. Genetic diversity of avian avulavirus 1 (Newcastle disease virus genotypes VIg and VIIb) circulating in wild birds in Kazakhstan. Arch Virol. 2018 Jul;163(7):1949-1954. https://doi.org/10.1007/s00705-018-3815-9

21.Zhugunissov K, Bulatov Y, Taranov D, Yershebulov Z, Koshemetov Z, Zhunushov A, Renukaradhya GJ, Tabynov K, Abduraimov Y. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage. Vet Microbiol. 2018 Nov;226:23-30. https://doi.org/10.1016/j.vetmic.2018.10.003

22.Asanzhanova NN, Ryskeldinova SZ, Chervyakova OV, Khairullin BM, Kasenov MM, Tabynov KK. Comparison of Different Methods of Purification and Concentration in Production of Influenza Vaccine. Bull Exp Biol Med. 2017 Dec;164(2):229-232. https://doi.org/10.1007/s10517-017-3964-y

23.Dhakal S, Hiremath J, Bondra K, Lakshmanappa YS, Shyu DL, Ouyang K, Kang KI, Binjawadagi B, Goodman J, Tabynov K, Krakowka S, Narasimhan B, Lee CW, Renukaradhya GJ. Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. J Control Release. 2017 Feb 10;247:194-205. https://doi.org/10.1016/j.jconrel.2016.12.039

24.Mailybayeva A, Yespembetov B, Ryskeldinova S, Zinina N, Sansyzbay A, Renukaradhya GJ, Petrovsky N, Tabynov K. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats. PLoS One. 2017 Oct 12;12(10):e0186484. https://doi.org/10.1371/journal.pone.018648

25.Tabynov K. Influenza viral vector based Brucella abortus vaccine: a novel vaccine candidate for veterinary practice. Expert Rev Vaccines. 2016 Oct;15(10):1237-9. https://doi.org/10.1080/14760584.2016.1208089

26.Tabynov K, Orynbayev M, Renukaradhya GJ, Sansyzbay A. Simultaneous subcutaneous and conjunctival administration of the influenza viral vector based Brucella abortus vaccine to pregnant heifers provides better protection against B. abortus 544 infection than the commercial B. abortus S19 vaccine. Vaccine. 2016 Sep 30;34(42):5049-5052. https://doi.org/10.1016/j.vaccine.2016.08.072

27.Tabynov K, Yespembetov B, Matikhan N, Ryskeldinova S, Zinina N, Kydyrbayev Z, Assanzhanova N, Tabynov K, Renukaradhya GJ, Mukhitdinova G, Sansyzbay A. First evaluation of an influenza viral vector based Brucella abortus vaccine in sheep and goats: Assessment of safety, immunogenicity and protective efficacy against Brucella melitensis infection. Vet Microbiol. 2016 Dec 25;197:15-20. https://doi.org/10.1016/j.vetmic.2016.11.001

28.Tabynov K, Yespembetov B, Ryskeldinova S, Zinina N, Kydyrbayev Z, Kozhamkulov Y, Inkarbekov D, Sansyzbay A. Prime-booster vaccination of cattle with an influenza viral vector Brucella abortus vaccine induces a long-term protective immune response against Brucella abortus infection. Vaccine. 2016 Jan 20;34(4):438-444. https://doi.org/10.1016/j.vaccine.2015.12.028

29.Tabynov K, Sansyzbay A, Tulemissova Z, Tabynov K, Dhakal S, Samoltyrova A, Renukaradhya GJ, Mambetaliyev M. Inactivated porcine reproductive and respiratory syndrome virus vaccine adjuvanted with Montanide™ Gel 01 ST elicits virus-specific cross-protective inter-genotypic response in piglets. Vet Microbiol. 2016 Aug 30;192:81-89. https://doi.org/10.1016/j.vetmic.2016.06.014

30.Tabynov K, Ryskeldinova S, Sansyzbay A. An influenza viral vector Brucella abortus vaccine induces good cross-protection against Brucella melitensis infection in pregnant heifers. Vaccine. 2015 Jul 17;33(31):3619-23. https://doi.org/10.1016/j.vaccine.2015.06.045

31.Tabynov K, Kydyrbayev Z, Ryskeldinova S, Assanzhanova N, Kozhamkulov Y, Inkarbekov D, Sansyzbay A. Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine. Aust Vet J. 2014 Nov;92(11):450-7. https://doi.org/10.1111/avj.12248

32.Tabynov K, Sansyzbay A, Sandybayev N, Mambetaliyev M. The pathogenicity of swan derived H5N1 virus in birds and mammals and its gene analysis. Virol J. 2014 Nov 29;11:207. https://doi.org/10.1186/s12985-014-0207-y

33.Tabynov K, Yespembetov B, Sansyzbay A. Novel vector vaccine against Brucella abortus based on influenza A viruses expressing Brucella L7/L12 or Omp16 proteins: evaluation of protection in pregnant heifers. Vaccine. 2014 Oct 14;32(45):5889-92. https://doi.org/10.1016/j.vaccine.2014.08.073

34.Tabynov K, Sansyzbay A, Kydyrbayev Z, Yespembetov B, Ryskeldinova S, Zinina N, Assanzhanova N, Sultankulova K, Sandybayev N, Khairullin B, Kuznetsova I, Ferko B, Egorov A. Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virol J. 2014 Apr 10;11:69. https://doi.org/10.1186/1743-422X-11-69

35.Tabynov K, Kydyrbayev Zh, Ryskeldinova Sh, Assanzhanova N, Sansyzbay A. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza. Vaccine. 2014 May 23;32(25):2965-71. https://doi.org/10.1016/j.vaccine.2014.03.095

36.Tabynov K, Kydyrbayev Z, Ryskeldinova S, Yespembetov B, Zinina N, Assanzhanova N, Kozhamkulov Y, Inkarbekov D, Gotskina T, Sansyzbay A. Novel influenza virus vectors expressing Brucella L7/L12 or Omp16 proteins in cattle induced a strong T-cell immune response, as well as high protectiveness against B. abortus infection. Vaccine. 2014 Apr 11;32(18):2034-41. https://doi.org/10.1016/j.vaccine.2014.02.058

37.Tabynov K, Kydyrbayev Z, Sansyzbay A, Khairullin B, Ryskeldinova S, Assanzhanova N, Kozhamkulov Y, Inkarbekov D. Immunogenic and protective properties of the first Kazakhstan vaccine against pandemic influenza A (H1N1) pdm09 in ferrets. Virol Sin. 2012 Dec;27(6):345-52. https://doi.org/10.1007/s12250-012-3272-7

Media about us

1. https://kazpravda.kz/n/uchenyy-allergik-ispytaet-svoyu-vaktsinu-na-sebe/

2.https://khabar.kz/ru/news/nauka-i-obrazovanie/item/149915-v-almaty-startoval-forum-molodykh-uchenykh-asfen-forum

3.https://news.kaznmu.edu.kz/%D0%B8%D0%B7%D0%B1%D0%B0%D0%B2%D0%B8%D1%82%D1%8C%D1%81%D1%8F-%D0%BE%D1%82-%D0%B0%D0%BB%D0%BB%D0%B5%D1%80%D0%B3%D0%B8%D0%B8-%D0%B7%D0%B0-%D0%BC%D0%B5%D1%81%D1%8F%D1%86-%D0%BA%D0%B0%D0%B7-2/

4. https://baigenews.kz/kazahstanskie-uchyonye-razrabatyvayut-novuyu-vaktsinu-ot-allergii_154022/

5. https://bizmedia.kz/2023/06/05/kazahstanskie-uchenye-na-pyatoj-stadii-sozdaniya-vakcziny-ot-allergii/

6. https://halyq-uni.kz/news/20959-kazakstandyk-galymdar-allergiia-men-demikpeni-emdeitin-vaktsina-zirledi/amp/

7. https://kazpravda.kz/n/pomoshch-allergikam/

8.https://the-steppe.com/lyudi/kak-razrabatyvayut-vakcinu-protiv-koronavirusa-i-kto-zanimaetsya-etim-v-kazahstane?fbclid=IwAR3fJCfAUPU5ubcIRhDKBLo-bDQWwLwSJzOCVmjbYXUdvyw8--dFam4GWm8#

9.https://aikyn.kz/63061/vakcina-salghyzyp-uekimetting-nazaryn-awdarghym-keldi-virwsolog-vakcinolog-professor-irwsolog-vakcinolog-professor/?fbclid=IwAR32QiXDFEJsnQD5NawVuOeApDbG94knuFhgfDX5arRhufhbTup8LnR0yro

10.https://ru.sputnik.kz/health/20200922/15026632/Kazakhstan-razrabatyvaet-bezynektsionnuyu-vaktsinu-ot-koronavirusa.html?fbclid=IwAR3TYPP1uxEHq9-gKRJ7Phvt24qazVu7A3wTsyTmn84ppYGqOyr5xdYymNA

11.https://ru.sputnik.kz/radio/20201102/15367462/kazakhstan-vaktsina-allergiya.html?fbclid=IwAR3fBRZvs7tUokPGr8VM1f8Uenk-cEdqjpipAO2mCd-S8l_HZSaWzbg3yu4

12.https://tengrinews.kz/kazakhstan_news/kazahstanskiy-uchenyiy-vvel-vtoruyu-vaktsinu-protiv-420864/?fbclid=IwAR1xfTeZIz1mb_GS5S1oKeIKyCDXhkhbu_spShUHUbFVhorQUGxdOf1_pCw

13. https://tengrinews.kz/kazakhstan_news/nazarbaev-nazval-imena-molodyih-kazahstantsev-kotoryimi-422897/?fbclid=IwAR1k2xfpuJz-diG5dAQXVxnIOVi0UvLufpGYPEgbCjQbd0ZBCtYt0-uU8Ac

14. https://www.youtube.com/watch?v=6z-6gf1THeQ

15.https://anatili.kazgazeta.kz/news/58866?fbclid=IwAR3BOwR11QSMS12aMjIFJvJT4L1Q_bT4dxGd3ar22ftJNHbFyvwzgA1I4aE

16.https://www.kazpravda.kz/news/prezident2/eshche-dve-kazahstanskie-vaktsini-ot-covid-19-vklucheni-v-reestr-voz---tokaev?fbclid=IwAR0GmC5ORarN-Jl5e3NSABQOauZ2an-cX5u1HaTEkBgcv4Z5IE3ya4ExNDA

17. https://www.kazpravda.kz/news/obshchestvo/chto-izvestno-o-novoi-kazahstanskoi-vaktsine-naruvax-

18. https://tengrinews.kz/kazakhstan_news/vaktsinu-protiv-covid-19-koshek-prezentovali-nur-sultane-451862/

19.https://ru.sputnik.kz/health/20211021/18472241/Pervuyu-kazakhstanskuyu-vaktsinu-protiv-COVID-19-dlya-koshek-prezentovali-v-Nur-Sultane.html

20. https://www.kt.kz/rus/covid-19/v_kazahstane_sozdali_vaktsinu_protiv_covid-19_dlya_koshek_1377923467.html

21. https://informburo.kz/novosti/kazahstanskuyu-vakcinu-ot-koronavirusa-dlya-koshek-predstavili-v-nur-sultane

22. https://tass.ru/obschestvo/12739301

23. https://inbusiness.kz/ru/last/na-vystavke-kazagro-pokazali-vakcinu-protiv-covid-19-dlya-koshek

24. https://newtimes.kz/obshchestvo/138415-vaktsinu-protiv-kvi-dlia-koshek-prezentovali-v-nur-sultane

25. https://vestikavkaza.ru/news/kazahstan-sozdal-pervuu-otecestvennuu-antikoronavirusnuu-vakcinu-dla-kosek.html

26.https://www.nur.kz/health/coronavirus/1938189-tri-novye-vaktsiny-protiv-koronavirusa-poyavyatsya-v-kazahstane-odnoy-iz-nih-mozhno-privitsya-doma/

27.https://orda.kz/v-kazahstane-razrabotali-vakcinu-ot-covid-19-dlja-koshek-chto-o-nej-izvestno/

28.https://ratel.kz/kaz/v_nur_sultane_predstavili_vaktsinu_ot_covid_19_dlja_koshek

29. https://365info.kz/2021/10/kiski-tozhe-v-zone-riska-vaktsinu-ot-kvi-vypustili-dlya-koshek-v-kazahstane

30. https://www.sb.by/articles/v-kazakhstane-razrabotali-veterinarnuyu-vaktsinu-ot-koronavirusa-dlya-koshek.html?amp=1

31. https://ulysmedia.kz/news/1531-kazakhstanskuiu-vaktsinu-ot-covid-19-dlia-koshek-prezentovali-v-stolitse/

32. https://www.kazpravda.kz/news/obshchestvo/vaktsinu-protiv-covid-19-dlya-pushnih-zhivotnih-razrabotali-kazahstanskie-virusologi

33. https://informburo.kz/novosti/zooparki-kazahstana-mogut-besplatno-vakcinirovat-tigrov-i-lvov-protiv-covid-19

34. https://paryz.kz/kazakhstan-news/12496-kazakhstanskii-uchenyi-prizval-vladeltsev-zooparkov-vaktsinirovat-tigrov-i-lvov

35. https://orda.kz/zooparkam-kazahstana-predlozhili-besplatno-vakcinirovat-predstavitelej-koshachih-ot-covid-19/

36. https://www.youtube.com/watch?v=_oyeoIrgZzo

37. https://youtu.be/o1yr1UcCPzM

38. https://youtu.be/C24KjZcQMoY

39. https://youtu.be/iz6DgahEgws

40. https://youtu.be/ptwq-HsBYKE

41. https://youtu.be/C4AWmcp5PZE

42. https://youtu.be/Vd8ljAbfnK8

43. https://youtu.be/xk0q8vpklxA

44. https://youtu.be/nUD8lzVC1GM

45. https://youtu.be/lFN8egJv-kE

46. https://youtu.be/cSYBfr4E6rY

47. https://youtu.be/YXkTWhy-bro

48. https://pharmnewskz.com/ru/news/kazahstanskaya-vakcina-ot-allergii-proshla-doklinicheskie-ispytaniya_20532